-+ 0.00%
-+ 0.00%
-+ 0.00%

Sartorius Stedim Biotech Affirms FY26 Sales Revenue Growth Guidance

MT Newswires·07/23/2026 02:09:19
Listen to the news
02:09 AM EDT, 07/23/2026 (MT Newswires) -- Sartorius Stedim Biotech (DIM.PA) reiterated its guidance for growth in sales revenue for full-year 2026. The France-listed biopharmaceutical group continues to expect a 6% to 10% increase in sales revenue for the year in constant currencies, noting that the outlook incorporates tariff environment changes.